

DIVI'S LABORATOROES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31st DECEMBER, 2011
(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Period ended		Year Ended
		31.12.2011	30.09.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	(a) Net Sales/Income from operations (Net of Excise Duty)	41468	35408	31005	112731	82590	130544
	(b) Other Operating Income	274	40	492	629	830	958
	Total Income	41742	35448	31497	113360	83420	131502
2	<u>Expenditure:</u>						
	a. (Increase) / Decrease in Stock- in- Trade and Work-in-Progress	(4242)	(469)	1105	(8337)	558	3452
	b. Consumption of Raw Material	20403	14893	10741	53204	31774	48668
	c. Purchase of Traded Goods	0	0	0	0	0	0
	d. Employees Cost	3590	3237	2745	10123	7542	11206
	e. Depreciation	1620	1520	1352	4540	3990	5335
	f. Other Expenditure						
	- Manufacturing Expenses	3745	3066	2669	9805	7311	10207
	- Other expenses	3136	2060	1889	7705	4954	7565
	g. Total	28252	24307	20501	77040	56129	86433
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	13490	11141	10996	36320	27291	45069
4	Other Income	2570	2234	709	6130	1979	2902
5	Profit before Interest & Exceptional Items (3+4)	16060	13375	11705	42450	29270	47971
6	Finance Charges	20	59	56	101	163	66
7	Profit after Interest but before Exceptional Items (5-6)	16040	13316	11649	42349	29107	47905
8	Exceptional items	0	0	0	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	16040	13316	11649	42349	29107	47905
10	Tax Expense						
	- Current Tax	3040	2445	1190	7950	2600	3920
	- MAT Credit Utilisation	366	125	111	751	184	128
	- Deferred Tax	379	141	191	529	241	300
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	12255	10605	10157	33119	26082	43557
12	Extra-ordinary items	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	12255	10605	10157	33119	26082	43557
14	Paid-up Equity Share Capital (Face Value: Rs.2 each)	2654	2653	2651	2654	2651	2652
15	Reserves excluding revaluation						180153

	reserves						
16	Earnings per Share						
a)	Basic Earnings Per Share before extra-ordinary items Rs.	9.24	8.00	7.68	24.97	19.71	32.90
	Diluted Earnings Per Share before extra-ordinary items Rs.	9.24	7.99	7.67	24.97	19.70	32.88
b)	Basic Earnings Per Share after extra-ordinary items Rs.	9.24	8.00	7.68	24.97	19.71	32.90
	Diluted Earnings Per Share after extra-ordinary items Rs.	9.24	7.99	7.67	24.97	19.70	32.88
17	Public shareholding:						
	- No. of shares	63481010	63454450	63380320	63481010	63380320	63372210
	- % of shareholding	47.84%	47.83%	47.81%	47.84%	47.81%	47.79%
18	Promoters and promoter group shareholding:						
	a) pledged / encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	b) non-encumbered:						
	No. of shares	69222100	69222100	69185100	69222100	69185100	69222900
	Percentage of shares (as a % of the total shareholding of the promoter group)	100%	100%	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	52.16%	52.17%	52.19%	52.16%	52.19%	52.21%

NOTES:

1. The above results for the period ended 31st December 2011, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 28th January, 2012 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited Standalone Results and to publish consolidated results at the year end.
4. Accounts have been reclassified as per the revised Schedule VI to Companies Act, 1956. Directors' Remuneration which was included earlier under Other Expenditure has now been included under Employee Cost. Figures for the previous year/periods have also been regrouped or recasted, wherever necessary.
5. During the current quarter, the company has allotted 26,560 equity shares of Rs.2/- each to the employees on exercise of their stock options.
6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31.12.2011:
Opening: Nil, Received during the Quarter: 15, Resolved: 15, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 28-01-2012

Dr. Murali K. Divi
Chairman & Managing Director